We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases Draft Guidance on Development of Vulvovaginal Candidiasis Drugs
FDA Releases Draft Guidance on Development of Vulvovaginal Candidiasis Drugs
Drugmakers developing treatments for uncomplicated vulvovaginal candidiasis should conduct two adequate and well-controlled clinical trials with a superiority design to demonstrate efficacy, the FDA recommends.